Peregrine Pharmaceuticals Inc. (CDMO)

Last Three Months

27-Jan-24 -- 26-Apr-24

Time Period:

Three Months
|
Year

0 Net Amount

Buy:	0	--
Sell:	0	--

Company Sentiment

Biotechnology

Drugs

Insider Trading Sentiment: Reduce

Sentiment Breakdown by Insider

0

(3)

0

(2)

0

(1)

20

0

4

+1

0

+2

0

+3

Two Year Chart

27-Apr-22 -- 26-Apr-24

Price ($)

Two Year Stock Price Chart

Sentiment

Buy & Sell Volume ($)

Two Year Insider Trading Volume Chart

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
11-Apr-24 7:41 PM View:	09-Apr-24 Option Exercise 0	Hart Daniel Ryan Chief Financial Officer		Peregrine Pharmaceuticals Inc. - CDMO	7% 79.31K to 85.05K	0	0	--	--	Show Txns Hide Txns

11-Apr-24 7:44 PM View:	09-Apr-24 Option Exercise 0	Ziebell Mark R V. P., General Counsel		Peregrine Pharmaceuticals Inc. - CDMO	5% 63.27K to 66.48K	0	0	--	--	Show Txns Hide Txns

11-Apr-24 7:40 PM View:	09-Apr-24 Option Exercise 0	Green Nicholas Stewart President & CEO Director		Peregrine Pharmaceuticals Inc. - CDMO	12% 192.49K to 215.37K	0	0	--	--	Show Txns Hide Txns

11-Apr-24 7:43 PM View:	09-Apr-24 Option Exercise 0	Richieri Richard A. Chief Operations Officer		Peregrine Pharmaceuticals Inc. - CDMO	9% 30.83K to 33.6K	0	0	--	--	Show Txns Hide Txns

12-Apr-24 7:35 PM View:	11-Apr-24 Option Exercise 0	Kwietniak Matthew R. Chief Commercial Officer		Peregrine Pharmaceuticals Inc. - CDMO	16% 19.83K to 23.03K	0	0	--	--	Show Txns Hide Txns